Found: 78
Select item for more details and to access through your institution.
Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs.
- Published in:
- 2019
- By:
- Publication type:
- journal article
GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study.
- Published in:
- Frontiers in Endocrinology, 2024, p. 1, doi. 10.3389/fendo.2024.1414101
- By:
- Publication type:
- Article
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience.
- Published in:
- Pituitary, 2022, v. 25, n. 6, p. 831, doi. 10.1007/s11102-022-01266-4
- By:
- Publication type:
- Article
Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis.
- Published in:
- Pituitary, 2018, v. 21, n. 4, p. 414, doi. 10.1007/s11102-018-0892-4
- By:
- Publication type:
- Article
Correction to: Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
- Published in:
- Pituitary, 2018, v. 21, n. 3, p. 309, doi. 10.1007/s11102-018-0878-2
- By:
- Publication type:
- Article
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
- Published in:
- Pituitary, 2018, v. 21, n. 3, p. 302, doi. 10.1007/s11102-018-0873-7
- By:
- Publication type:
- Article
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
- Published in:
- Pituitary, 2015, v. 18, n. 3, p. 385, doi. 10.1007/s11102-014-0585-6
- By:
- Publication type:
- Article
Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
- Published in:
- 2015
- By:
- Publication type:
- Erratum
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review.
- Published in:
- Pituitary, 2014, v. 17, n. 3, p. 267, doi. 10.1007/s11102-013-0500-6
- By:
- Publication type:
- Article
Hypothalamitis: a diagnostic and therapeutic challenge.
- Published in:
- Pituitary, 2014, v. 17, n. 3, p. 197, doi. 10.1007/s11102-013-0487-z
- By:
- Publication type:
- Article
Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study.
- Published in:
- Pituitary, 2012, v. 15, n. 4, p. 571, doi. 10.1007/s11102-011-0370-8
- By:
- Publication type:
- Article
Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma.
- Published in:
- 2011
- By:
- Publication type:
- Report
High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas.
- Published in:
- Pituitary, 2011, v. 14, n. 4, p. 299, doi. 10.1007/s11102-011-0293-4
- By:
- Publication type:
- Article
Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly.
- Published in:
- Pituitary, 2009, v. 12, n. 3, p. 196, doi. 10.1007/s11102-008-0157-8
- By:
- Publication type:
- Article
Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency.
- Published in:
- Pituitary, 2008, v. 11, n. 1, p. 55, doi. 10.1007/s11102-007-0069-z
- By:
- Publication type:
- Article
The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype?
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 3, p. 1895, doi. 10.3390/ijms25031895
- By:
- Publication type:
- Article
Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 21, p. 15719, doi. 10.3390/ijms242115719
- By:
- Publication type:
- Article
Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
- Published in:
- Journal of Neuro-Oncology, 2016, v. 126, n. 3, p. 519, doi. 10.1007/s11060-015-1991-y
- By:
- Publication type:
- Article
Periovulatory Plasma Prolactin Response to Gonadotropin-Releasing Hormone: Role of Endogenous Opiates.
- Published in:
- Neuroendocrinology, 1990, v. 51, n. 6, p. 717, doi. 10.1159/000125416
- By:
- Publication type:
- Article
Naloxone Inhibition of Postprandial Growth Hormone Releasing Hormone-Induced Growth Hormone Release in Obesity.
- Published in:
- Neuroendocrinology, 1989, v. 50, n. 5, p. 529, doi. 10.1159/000125276
- By:
- Publication type:
- Article
Relationships between Intracranial Pressure and Diurnal Prolactin Secretion in Primary Empty Sella.
- Published in:
- Neuroendocrinology, 1984, v. 38, n. 2, p. 102, doi. 10.1159/000123876
- By:
- Publication type:
- Article
Estradiol Modulation of Basal and Gonadotropin-Releasing Hormone-Induced Gonadotropin Release in Intact and Castrated Men.
- Published in:
- Neuroendocrinology, 1983, v. 36, n. 2, p. 105, doi. 10.1159/000123445
- By:
- Publication type:
- Article
First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome.
- Published in:
- Frontiers in Endocrinology, 2019, p. N.PAG, doi. 10.3389/fendo.2019.00365
- By:
- Publication type:
- Article
Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool.
- Published in:
- European Journal of Endocrinology, 2022, v. 187, n. 5, p. 719, doi. 10.1530/EJE-22-0454
- By:
- Publication type:
- Article
Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.
- Published in:
- European Journal of Endocrinology, 2022, v. 186, n. 3, p. P1, doi. 10.1530/EJE-21-0977
- By:
- Publication type:
- Article
More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.
- Published in:
- European Journal of Endocrinology, 2021, v. 185, n. 4, p. 525, doi. 10.1530/EJE-21-0239
- By:
- Publication type:
- Article
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.
- Published in:
- European Journal of Endocrinology, 2021, v. 184, n. 2, p. 217, doi. 10.1530/EJE-20-0767
- By:
- Publication type:
- Article
Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study.
- Published in:
- European Journal of Endocrinology, 2020, v. 182, n. 6, p. 583, doi. 10.1530/EJE-19-0762
- By:
- Publication type:
- Article
Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis.
- Published in:
- European Journal of Endocrinology, 2018, v. 178, n. 2, p. L1, doi. 10.1530/EJE-17-0910
- By:
- Publication type:
- Article
Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
- Published in:
- European Journal of Endocrinology, 2016, v. 174, n. 3, p. 307, doi. 10.1530/EJE-15-0586
- By:
- Publication type:
- Article
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.
- Published in:
- European Journal of Endocrinology, 2016, v. 174, n. 2, p. 241, doi. 10.1530/EJE-15-0832
- By:
- Publication type:
- Article
GH receptor isoforms and skeletal fragility in acromegaly.
- Published in:
- European Journal of Endocrinology, 2014, v. 171, n. 2, p. 237, doi. 10.1530/EJE-14-0205
- By:
- Publication type:
- Article
Hypopituitarism after traumatic brain injury.
- Published in:
- European Journal of Endocrinology, 2005, v. 152, n. 5, p. 679, doi. 10.1530/eje.1.01895
- By:
- Publication type:
- Article
The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2024, v. 109, n. 5, p. 1341, doi. 10.1210/clinem/dgad673
- By:
- Publication type:
- Article
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2024, v. 109, n. 1, p. e58, doi. 10.1210/clinem/dgad493
- By:
- Publication type:
- Article
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Natural history of TFR2-related hereditary hemochromatosis in a 47-yr-old Italian patient.
- Published in:
- 2009
- By:
- Publication type:
- Letter
Increased Prevalence of Radiological Spinal Deformities in Adult Patients With GH Deficiency: Influence of GH Replacement Therapy.
- Published in:
- Journal of Bone & Mineral Research, 2006, v. 21, n. 4, p. 520, doi. 10.1359/jbmr.060112
- By:
- Publication type:
- Article
Increased Prevalence of Radiological Spinal Deformities in Active Acromegaly: A Cross-Sectional Study in Postmenopausal Women.
- Published in:
- Journal of Bone & Mineral Research, 2005, v. 20, n. 10, p. 1837, doi. 10.1359/JBMR.050603
- By:
- Publication type:
- Article
Influence of Growth Hormone Receptor d3 and Full-Length Isoforms on Biochemical Treatment Outcomes in Acromegaly.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2009, v. 94, n. 6, p. 2015, doi. 10.1210/jc.2008-1337
- By:
- Publication type:
- Article
Prevalence of Vertebral Fractures in Men with Acromegaly.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2008, v. 93, n. 12, p. 4649, doi. 10.1210/jc.2008-0791
- By:
- Publication type:
- Article
Microalbuminuria in Insulin Sensitivity in Patients with Growth Hormone-Secreting Pituitary Tumor.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2008, v. 93, n. 3, p. 710, doi. 10.1210/jc.2007-1197
- By:
- Publication type:
- Article
Residual Pituitary Function after Brain Injury-Induced Hypopituitarism: A Prospective 12-Month Study.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2005, v. 90, n. 11, p. 6085, doi. 10.1210/jc.2005-0504
- By:
- Publication type:
- Article
Primary Empty Sella.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2005, v. 90, n. 9, p. 5471, doi. 10.1210/jc.2005-0288
- By:
- Publication type:
- Article
De-escalation treatment with pasireotide for acromegaly: a long-term experience.
- Published in:
- Endocrine (1355008X), 2023, v. 80, n. 3, p. 505, doi. 10.1007/s12020-023-03325-7
- By:
- Publication type:
- Article
Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients?
- Published in:
- Endocrine (1355008X), 2023, v. 80, n. 1, p. 142, doi. 10.1007/s12020-022-03261-y
- By:
- Publication type:
- Article
Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly.
- Published in:
- Endocrine (1355008X), 2022, v. 78, n. 2, p. 343, doi. 10.1007/s12020-022-03158-w
- By:
- Publication type:
- Article
Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant.
- Published in:
- Endocrine (1355008X), 2021, v. 73, n. 3, p. 658, doi. 10.1007/s12020-021-02711-3
- By:
- Publication type:
- Article